Peter Suzdak

Peter has more than 29 years of experience in the U.S. and European-based Pharmaceutical companies and has established multiple Research and Development organizations which have resulted in the filing of 17 INDs and 3 NDA/NDA's. Most recently Peter was CEO of Rexahn Pharmaceuticals where he refocused and recapitalized the company raising $75M in public financings. Peter has also co-Founded Artesian Therapeutics (which was acquired by Cardiome Pharma), Cardioxyl Pharmaceuticals (which was acquired by Bristol-Myers Squibb), and Corridor Pharmaceuticals (which was acquired by AstraZeneca). Peter has raised more than $43M in venture capital financings and $75M in public financings.

Peter’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, and as Director of Neurobiology for Novo Nordisk. Peter was also a PRAT fellow at the National Institute of Mental Health (NIMH). Peter holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.